The immunogenetics of smallpox vaccination.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0022-1899 (Print) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE
    • Publication Information:
      Publication: Jan. 2011- : Oxford : Oxford University Press
      Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press
    • Subject Terms:
      Genetic Predisposition to Disease*; Fever/*genetics ; Smallpox Vaccine/*adverse effects ; Vaccination/*adverse effects ; Vaccines, Attenuated/*adverse effects; Adult ; Female ; Fever/immunology ; Fever/virology ; Follow-Up Studies ; Haplotypes ; Humans ; Interleukin-1/genetics ; Interleukin-18/genetics ; Interleukin-4/genetics ; Male ; Middle Aged ; Receptors, Interleukin-1 Type I/genetics ; Smallpox Vaccine/immunology ; Vaccines, Attenuated/immunology
    • Abstract:
      We hypothesized that individuals who develop fever after smallpox vaccination have genetically determined differences in their immune responses to vaccinia virus. We looked for an association between the development of fever and single-nucleotide polymorphisms (SNPs) in 19 candidate genes in 346 individuals previously assessed for clinical responses to smallpox vaccination. Fever after smallpox vaccination is associated with specific haplotypes in the interleukin (IL)-1 gene complex and in the IL18 gene. A haplotype in the IL4 gene was highly significant for reduced susceptibility to the development of fever after vaccination among vaccinia-naive individuals. Our results indicate that certain haplotypes in the IL-1 gene complex and in IL18 and IL4 predict an altered likelihood of the development of fever after smallpox vaccination. Our findings also raise the possibility that these same haplotypes may identify individuals at risk for the development of fever after receipt of other live virus vaccines, providing information that could be useful in anticipating and preventing more-serious adverse events.
    • Comments:
      Comment in: J Infect Dis. 2007 Jul 15;196(2):176-7. (PMID: 17570102)
    • Grant Information:
      HG01720 United States HG NHGRI NIH HHS; N01-AI-25464 United States AI NIAID NIH HHS; U54-AI057160 United States AI NIAID NIH HHS
    • Accession Number:
      0 (IL1R1 protein, human)
      0 (IL4 protein, human)
      0 (Interleukin-1)
      0 (Interleukin-18)
      0 (Receptors, Interleukin-1 Type I)
      0 (Smallpox Vaccine)
      0 (Vaccines, Attenuated)
      207137-56-2 (Interleukin-4)
    • Publication Date:
      Date Created: 20070616 Date Completed: 20070906 Latest Revision: 20071203
    • Publication Date:
      20240628
    • Accession Number:
      10.1086/518794
    • Accession Number:
      17570108